Aerobiotix

Aerobiotix Collaborates With Cardinal Health to Get Clean Air Technology Into More Hospitals and Surgical Centers

Retrieved on: 
Monday, September 27, 2021
Other Manufacturing, Medical Devices, Surgery, Construction & Property, Infectious Diseases, Hospitals, Building Systems, Manufacturing, General Health, Health, Paola Lattus, Food, HEPA, Efficiency, Health, Solution, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, FDA, Cardinal Health, Volatile organic compound, MD, Hospital, Virus, Bacteria, Cardinal, Marketing, Essential, CEO, Program, SARS-COV-2, Risk, Technology, Organization, Subclinical infection, Education, Medical device, Pharmaceutical industry, Aerobiotix, Cardinal Health, AEROBIOTIX, CARDINAL HEALTH

Thanks to a new distribution agreement with Cardinal Health, its technology will soon be available in more hospitals and surgical centers to help reduce the risk of infection and contamination of infectious aerosols including SARS-COV-2.

Key Points: 
  • Thanks to a new distribution agreement with Cardinal Health, its technology will soon be available in more hospitals and surgical centers to help reduce the risk of infection and contamination of infectious aerosols including SARS-COV-2.
  • Cardinal Health recently added Aerobiotix as a preferred supplier in their Performance Plus* program.
  • This program offers hospitals efficiency and value when selecting products, and Aerobiotix is the preferred supplier in the air quality product category.
  • Having an innovative product in our portfolio that is proven to improve the air quality in operating rooms and surgical centers is important to us, said Marc DeLorenzo, SVP Strategic Sourcing for Cardinal Health.

Aerobiotix Raises $25M Growth Equity Financing Led by Global Healthcare Investment Firm Vivo Capital

Retrieved on: 
Thursday, May 6, 2021
FDA, Technology, Finance, Surgery, Managed care, General Health, Professional services, Medical devices, Infectious diseases, Hospitals, Other Technology, Biotechnology, Science, Other Science, Research, Health, Finance, Private equity, Money, Economy, Entrepreneurship, Corporate finance, Equity securities, Venture capital, Growth capital, Aerobiotix, Vivo Capital, Asahi Kasei, AEROBIOTIX, VIVO CAPITAL, ASAHI KASEI

b'Founded in 2013, Aerobiotix, a rapidly growing global medical company has raised a $25 million of growth equity financing.

Key Points: 
  • b'Founded in 2013, Aerobiotix, a rapidly growing global medical company has raised a $25 million of growth equity financing.
  • The round was led by Vivo Capital with participation by Asahi Kasei Ventures.
  • The strong commercial traction Aerobiotix has achieved with limited outside capital attests to the value of the Aerobiotix solution.
  • More information can be found at www.aerobiotix.com .\nFounded in 1996, Vivo Capital is a leading global healthcare investment firm with a diverse, multi-fund investment platform in venture capital, growth equity, buyout, and public equities.